MedTrace Logo

Omega 7 Oil and Inflammatory Biomarker Study

NCT03669575 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-10-15

No results posted yet for this study

Summary

The purpose of the study is to determine whether the palmitoleic acid supplementation can reduce the serum inflammatory biomarkers and low quality of life scores due to musculoskeletal discomfort. The study design is a 2-arm placebo-controlled double blind crossover trial. The randomized sequence of a single crossover is divided into 1:1 and each supplementation is three weeks with no washout in between.

Conditions

Interventions

DIETARY_SUPPLEMENT

omega 7

Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day

DIETARY_SUPPLEMENT

Placebo

Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7

Sponsors & Collaborators

  • Bastyr University

    lead OTHER

Principal Investigators

  • Masa Sasagawa, ND, PhD · Bastyr University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2019-06-30
Completion
2019-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669575 on ClinicalTrials.gov